A Dark Vector Cognition product

Item 5. Other Information.

2K characters. Original on sec.gov ·

Item 5. Other Information.

(a) – (b) Not applicable.

(c) The following provides a description of Rule 10b5-1 trading arrangements (as defined in Item 408 of Regulation S-K under the Exchange Act) adopted during the three months ended June 30, 2026, by any director or executive officer who is subject to the filing requirements of Section 16 of the Exchange Act:

On June 12, 2026, René F. Jones, Chairman of the Board and Chief Executive Officer, adopted a trading arrangement intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). The arrangement will terminate on or before March 31, 2027. Under the arrangement, a maximum aggregate number of 19,396 shares may be sold. In addition, a maximum aggregate number of 16,770 vested stock options may be exercised, and the underlying shares will be held by Mr. Jones after the withholding of shares to cover the cost of the exercise price of the options and tax obligations (also known as a net exercise and hold settlement). Transactions under the trading arrangement will not commence until completion of the required cooling off period under Rule 10b5-1 and expiration of any prior trading arrangement.

- 88 -

No executive officers and no directors terminated or modified a Rule 10b5-1 trading arrangement in the three months ended June 30, 2026.

Certain executive officers and directors have made elections to participate in, and are participating in, the Company's tax-qualified 401(k) plan and nonqualified deferred compensation plans, or have made, and may from time to time make, elections to reinvest dividends in M&T common stock, or have shares withheld to cover withholding taxes upon the vesting of equity awards or to pay the exercise price of options, each of which may be designed to satisfy the affirmative defense conditions of Rule 10b5-1(c) or may constitute non-Rule 10b5-1 trading arrangements (as defined in Item 408(c) of Regulation S-K).

Previous: Item 1A. Risk Factors. · Next: Item 6. Exhibits.